On Wednesday, Madrigal Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 74 to 90.
IBD's proprietary RS Rating identifies market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the last 52 weeks matches up against the rest of the market.
Over 100 years of market history shows that the market's biggest winners often have an RS Rating of above 80 as they launch their largest runs.
How To Use Stock Charts To Stay Profitable And Protected
Is Madrigal Pharmaceuticals Stock A Buy?
Madrigal Pharmaceuticals stock is trying to complete a cup without handle with a 299.98 buy point. See if the biotech stock can clear the breakout price in heavy trading.
The biotech firm posted 0% EPS growth in the latest quarterly report. Sales rose 0%.
Madrigal Pharmaceuticals stock holds the No. 189 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Halozyme Therapeutics and United Therapeutics are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
